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MINI ABSTRACT 
We present our 14-year experience of liver resection for hilar and peripheral 
cholangiocarcinomas with an analysis of the clinical and pathologic prognostic factors, overall 
survival and disease-free survival. 
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STRUCTURED ABSTRACT 
Objective 
The objective of this study was to analyze a single center's 14-year experience with 62 
consecutive patients with hilar (HCCA) and peripheral (PCCA) cholangiocarcinomas. 
Summary Background Data 
Long tenn survival achieved after surgical treatment ofHCCA and PCCA has been poor. 
Methods 
From March 1981 until December 1994, 62 consecutive patients with HCCA (n=28) and 
PCCA (n=34) underwent surgical treatment. Clinical and pathological risk factors were 
examined for prognostic influence. 
Results 
The survival rates for HCCA and PCCA at one-year were 79% (± 8%) and 67% (± 8%); at 
three years, 39<'10 (± 10%) and 40% (± 9%); and at five years, 8% (± 7%) and 35% (± 10%), 
respectively. The disease-free survival rates for HCCA and PCCA were 85% (±1O%) and 
77% (±9<'Io) at 1 year; 18% (±11%) and 41% (± 12%) at 3 years; and 18% (±11 %) and 41 % 
(±12%) at 5 years, respectively. With HCCA, no risk factors were associated with patient 
survival. For PCCA, multiple tumors (RR=3.5; 95% confidence interval=1.2 to 10.5) and 
incomplete resection (RR=8.3; 95% confidence interval=2.3 to 29.6) were independently 
associated with a worse prognosis. For HCCA, there was a trend for lower disease-free 
survival in female patients (p=O.056; logrank test). For PCCA, tumor size greater than 5 cm 
was the only factor associated with disease-recurrence (p=0.024; logrank) . Postoperative 
morbidity and mortality (30 day) were 32% and 14%, respectively for HCCA, and 24% and 
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6% forPCCA. 
Conclusions 
Even though rare, five year survival by resection can be achieved in both HCCA and PCCA; 
but new adjuvant treatments are clearly needed. 
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ABSTRACT 
Background. Long term survival achieved after surgical treatment of hilar 
cholangiocarcinoma (HCCA) and peripheral cholangiocarcinoma (PCCA) has been poor. 
Methods. During a 14-year period, 62 consecutive patients (HCCA=28, PCCA=34) 
underwent surgical treatment. The operations were individualized and included local excision 
of the tumor and supra pancreatic bile duct, lymph node dissection, vascular reconstruction 
and subtotal hepatectomy. Clinical and pathological risk factors were examined for prognostic 
influence. 
Results. Patients were followed for a median of25 months (12 to 102 months). Postoperative 
morbidity and mortality (30 day) were 32% and 14%, respectively for HCCA, and 24% and 
6% for PCCA. The survival rates for HCCA and PCCA at one-
year were 79"10 (± 8%) and 67% (± 8%); at three years, 39% (± 10%) and 40% (± 9%); and 
at five years, 8% (± 7%) and 35% (± 10%), respectively. The median survival was 24 (± 4) 
months for HCCA and 19 (±8) months for PCCA. The disease-free survival rates for HCCA 
and PCCA were 85% (±1O%) and 77% (j:9%) at 1 year; 18% (±11%) and 41% (± 12%) at 
3 years; and 18% (±11%) and 41% (±12%) at 5 years, respectively. Nearly 80% of these 
patients had TNM stage IV tumors. With HCCA, no risk factors were associated with patient 
survival. For PCCA, multiple tumors (RR=3.5; 95% confidence interval=1.2 to 10.5) and 
incomplete resection (RR=8.3; 95% confidence interval=2.3 to 29.6) were independently 
associated with a worse prognosis. For HCCA, there was a trend for lower disease-free 
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survival in female patients (p=O.056; logrank: test). For PCCA, tumor size greater than 5 cm 
was the only factor associated with disease-recurrence (p=O.024; logrank) . 
Conclusions. Even though rare, five year survival by resection can be achieved in both the 
HCCA and PCCA; but new adjuvant treatments are clearly needed. 
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INTRODUCTION 
Cholangiocarcinomas (CCA) arise from the bile duct epithelium. When the disease 
originates in the common hepatic duct as well as in the first and second bifurcations, it can 
be classified as hilar type (HCCA); whereas the peripheral intrahepatic type (PCCA) takes 
origin in a segmental duct or more peripheral duct (1-5). Duct cell carcinomas of the 
common and proper bile duct (6) and gallbladder were excluded from this study. Although 
there have been numerous reports of surgical treatment of HCCA and PCCA long term 
survival has been poor with few exceptions (7-12). In this report, we analyze our 14 year 
expenence. 
CASE MATERIAL AND METHODS 
Patients 
Between March 1981 and December 1994, 62 consecutive patients with hilar and 
peripheral cholangiocarcinomas underwent surgical treatment at the University of Pittsburgh 
Medical Center. There were 28 cases of HCCA and 34 cases ofPCCA. Patient follow-up 
(for survivors) as of December 1995, ranged from 15 to 102 months (median =22 months) 
for HCCA, and from 12 to 91 months (median=28 months) for PCCA. A retrospective 
review of all inpatient and outpatient records including operative and surgical pathology 
reports was performed. 
Preoperative Investigations 
Percutaneous transhepatic cholangiography and/or endoscopic retrograde 
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cholangiography were used to study the precise anatomical extension in HCCA. If indicated 
with HCCA, angiographic (hepatic artery, portal vein) studies were also performed. When 
total bilirubin exceeded 10 mgldl, percutaneous transhepatic biliary drainage was used 
(10,13,14). 
Prior to resection, the diagnosis of HCCA and PCCA was confirmed by either 
surgery, or percutaneous/endoscopic biopsy in 46% and 76%, respectively, of cases. 
Classification 
The tumors were divided into HCCA and PCCA categories primarily by their 
macroscopic location and extent, as detailed in surgical pathology reports and reviewed with 
available histologic material. In cases in which the classification was uncertain or ambiguous, 
the presence of epithelial dysplasia or carcinoma in situ was taken as an indication of origin 
from a major bile'duct and the tumor was designated as HCCA (15,16). 
The HCCA's were stratified by a modification of the Bismuth-Codette categories (17). 
Since the anatomic extension in nine cases precluded the use of this classification, we 
incorporated five new types: type IIIa+ when the tumor extended to the right anterior and 
posterior ducts; type Illb+ when the tumor extended up to the bile ducts of segments 4,3, and 
2; type IVa when the tumor extended to the second bifurcation in the right side; type IVb 
when there was extension to the bile ducts of segments 4,3 and 2; and type V when there 
was combination of IVa and IVb. Seven patients were classified as type IlIa, three as IIIa+, 
seven as IIIb, one as IV, two as IVa, two as IVb, and two as V. Four cases could not be 
classified (one patient had anatomic variations and in the other three, the extension of the 
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tumor was unclear by cholangiography and pathology) (Figure 1). 
Histopathology 
All tumors were mucin-secreting adenocarcinomas composed predominantly of small 
glands or single malignant cells embedded in a dense desmoplastic stroma (1-5,18,19). Two 
cases of HCCA and one case of PCCA showed focal papillary features. In six cases of 
PCCA, the cholangiocarcinoma was accompanied by foci of hepatocellular differentiation. 
Five cases ofHCCA and two cases ofPCCA had cirrhosis. 
Tumor Staging 
All patients were staged according to the pTNM classification for hilar and peripheral 
cholangiocarcinomas (20,21 ). [see Table I and IT]. In the HCCA group, 11 % of the patients 
were stage IT,ll % stage llI, 71% stage IVA and 7% stage IVB. In the PCCA group, 2% 
were stage L 190/0 stage IT, 31% stage ITI, 42% stage IVA and 6% stage IYB. 
The surgical resection was considered complete when all pathological margins were 
free of tumor or incomplete when margins were positive or when there was residual tumor. 
Surgical Procedures 
HCCA group --- Operations were individualized according to tumor extension and 
included local excision of the tumor and supra pancreatic bile duct with lymph node dissection 
in most cases. Vascular reconstruction and excision of the hepatic parenchyma were used 
when indicated. The liver resections comprised nine right trisegmentectomies (R T -T), one left 
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trisegmentectomy (LT-T), two right lobectomies (RT-L), one extended right lobectomy 
(Ext-RT), seven left lobectomies (LT-L), seven extended left lobectomies (Ext-LT) and one 
central excision (CE) (22-25). [ See Table ill] . Excision of the caudate lobe was done in 
20 of the 28 (71 %) patients (10,22-24). Systematic lymph node dissection was done in 24 
(86%) patients (10,12,26,27). There were nine vascular reconstructions, including: four 
segmental excision of main portal vein; one primary reconstruction of right portal vein; two 
segmental excisions of right hepatic artery; one primary reconstruction of the artery of the left 
lateral segment; and one replacement of both the main portal vein and proper hepatic artery 
graft with cadaver iliac vein and artery grafts, respectively (28-33). Biliary reconstruction 
was accomplished in all patients by Roux-en-Y hepatico-jejunostomy either to: one duct 
(n=17); two ducts (n=6); three ducts or more (n=5) (10,30-32,34). 
PCCA Group --- The standard approach was liver resection with lymph node 
dissection and/or vascular reconstruction when indicated. Liver resections comprised six RT-
T, one RT-T with wedge resection (WR) of the left lateral segment, four LT-T, five RT-L, 
three Ext-RT, one Ext-RT with right adrenalectomy, seven LT-L, five Ext-LT and two WR 
. Caudate lobe excision was done in 12 cases (35%) (22-24). Systematic lymph node 
dissection was performed in 18 (53%) of the 34 patients. Excision of the retrohepatic vena 
cava and replacement was performed in one case with a synthetic graft. A segment of main 
portal vein was excised in 3 patients with primary repair in 2 and replacement with a cadaveric 
vein allograft in the other. In one case, an iliac vein graft was used to empty a transected left 
hepatic vein to the inferior vena cava during RT-T. In five cases, biliary reconstruction with 
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Roux-en-Y hepatico-jejunostomy was required. 
Adjuvant Therapy 
HCCA-- Twenty four (85.7%) of the 28 patients survived the postoperative period. 
Of these 24, 22 (92%) received either radiotherapy (n=6), chemotherapy (n=I), or both 
(n=15) (35,36). 
PCCA-- Thirty-two (95%) of these 34 patients survived the postoperative period. 
Of the 32,24 (75%) received either radiotherapy (0=6), chemotherapy (n=15), or both (n=3). 
One patient underwent preoperative radiotherapy (36) . 
Prognostic Factors 
HCCA _·Sex, age, tumor differentiation, vascular invasion, lymph node involvement, 
type of operation, presence of underlying cirrhosis and tumor stage were analyzed. Because 
this tumor often involves the bifurcation of the common hepatic bile duct and usually does 
not fonn a discrete liver mass, it was not possible to accurately detennine tumor size, tumor 
distribution (unilobar vs bilobar) and tumor number (single vs multiple tumor). Adjuvant 
chemotherapy was not analyzable as a risk factor because over 90% of the patients received 
some fonn of treatment. 
PCCA--- The risk influence was analyzed of sex, age, tumor size, tumor distribution, 
number of tumors, vascular invasion, type of treatment, tumor stage, lymph node 
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involvement, and adjuvant treatment. Information on tumor differentiation was incomplete, 
and the effect of cirrhosis as a risk factor could not be analyzed because it was present in only 
6% of the patients. 
Statistical Analysis 
The standard two-sample t-test was used to compare group means while Pearson's 
chi-square test or Fishers Exact test was used to compare proportions. The Wilcoxon rank 
sum test, a non-parametric equivalent to the standard two-sample t-test was used for highly 
skewed data. 
Patient survival was calculated from the date of liver resection until death, and 
disease-free survival from the date of liver resection until the time of disease recurrence. 
Disease-free survival was calculated only for patients who had complete resection. Patients 
who were alive or disease-free as of December 1995 were censored. Disease recurrence was 
defined as measurable tumor by radiological studies or by laparotomy. Survival curves were 
generated using the Kaplan-Meier (product-limit) method (37) and were compared by the log-
rank (Mantel-Cox) test (38). For each survival rate, Greenwood's formula was used to 
calculate the standard error (39). Deaths within 30 days of surgery were defined as 
postoperative deaths. Analyses of risk factors were performed according to hilar and 
peripheral type of tumor. 
Cox's proportional hazards model was used to compute the relative risk (RR) of 
mortality and disease-recurrence, and 95% confidence intervals (40,41). A stepwise 
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multivariate analysis (backward elimination method) was performed using Cox's regression 
to identifY factors independently associated with mortality and disease-recurrence. Based on 
univariate analyses, the criterion for inclusion in the multivariate analysis was a p-value less 
than 0.05. 
One patient with PCCA had recurrent disease in the liver within seven months of 
surgery and underwent cluster transplantation (42). This patient died four years later with 
recurrent disease. For the analysis of patient survival, this patient was censored at the time 
of transplantation. Another patient with PCCA required orthotopic liver transplantation for 
liver failure one month after surgery. For the analysis of patient and disease-free survival, this 
patient was censored at time of transplantation. 
All tests were two-tailed. A p-value less than 0.05 was considered statistically 
significant. 
RESULTS 
Clinical Manifestations 
HCCA -- The most frequent complaint was jaundice (96%), followed by weight loss 
(29%), abdominal pain (20%), fever (16%) and hepatomegaly (a palpable mass) (4%) . 
PCCA -- The most frequent complaints were abdominal pain (71 %), hepatomegaly 
(34%), weight loss (15%) jaundice (12%) and fever (9%). One patient with PCCA had been 
exposed to Clonorchis sinensis (43). 
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Postoperative Morbidity and Mortality 
HCCA-- The postoperative (30 day) mortality rate was 14% (4/28). Complications 
occurred in nine patients (32%). The most common was bile leak and abscess (n=4; 19%), 
followed by subphrenic abscess (n=2; 7%), liver necrosis (n=2 ; 7%) and seroma (n=l; 4%). 
Of the nine complications, four patients required open drainage and one excision of the right 
anterior segment. Four patients died as a result of the complications. These complications 
were concentrated in the 14 patients with positive margins and the 9 patients who also 
required vascular reconstruction. However, the increased morbidity observed with 
incomplete resection was not significantly different than with complete resection (5/14 (36%) 
versus 4114 (25)010); p=1.0). Likewise, the increased morbidity in patients who required 
vascular reconstruction was not statistically different than those who did not require vascular 
reconstruction (5/9 (56%) versus 4119 (21%); p=O.lO). 
PCCA --- The postoperative mortality rate was 6% (2/34). Eight major 
complications occurred in eight patients (24%): bile leak and abscess (n=5; 15%), portal vein 
thrombosis (n=1; 3%), peritonitis (n=1; 3%) and cardiac arrest (n=1; 3%). Four of the eight 
complications were in the 10 patients with positive resection margins and the other 4 were 
in the five who required vascular reconstruction. The increased morbidity with incomplete 
resection was not statistically different than with complete resection (40% vs 17%; p=0.195). 
However, a higher rate of morbidity was observed in patients who required vascular 
reconstruction compared to patients who did not require vascular reconstruction (80% vs 
14%; p=0.0007). One of the patients who developed bile leak, abscess and biliary necrosis 
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had received preoperative radiotherapy and eventually was treated with orthotopic liver 
transplantation and recovered. The one patient with peritonitis required laparotomy and 
recovered. One patient died intraoperatively from cardiac arrest. 
Actuarial Patient Survival 
Kaplan-Meier patient survival according to hilar and peripheral type is shown in 
Figure 2. Survival rates for HCCA and PCCA at one-year were 79% (+ 8%) and 67% (+ 
8%); at three years, 39010 (+ 10%) and 40% (+ 9010); and at five years, 8% (+7%) and 35% 
(+ 10%), respectively. The median survival was 24 (+ 4 months) for HCCA and 19 (+ 8 
months) for PCCA. Patient survival according to type of treatment in HCCA and PCCA is 
shown in Figure 3. 
Seven patients have actual survival of 5 years or longer (table V), of which only one 
had HCCA. Six patients with PCCA have reached this milestone (median follow-up=89.5; 
range=75.3 to 167.7 months) of whom all had complete resections, had single tumors, and 
negative lymph nodes (table V). Five of the six patients had unilobar disease. 
Prognostic Factors: Univariate Analysis 
HCCA --- With univariate analysis, none of the clinical and pathologic risk factors 
were associated with patient survival. 
PCCA --- Worse survival (logrank) was associated with bilobar disease (p=O.029), 
multiple tumors (p=O.OOO5), vascular invasion (p=O.OO9), lymph node involvement (p=O.003), 
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and incomplete resection (p<O.OOOOI) (Figure 3). There was a trend for lower survival 
among patients whose tumor size was greater than 5 cm and who had an advanced stage 
(p=O.OS2). Survival was not influenced by adjuvant therapy (p=O.423). 
Disease-Free Survival 
Disease-free survival was calculated for patients who underwent complete resection 
(see statistical analysis section). The disease-free survival rates for HCCA and PCCA were 
85% (± 100/0) and 77% @:9%)at 1 year; 18% g; 11%) and 41% @: 12%) at 3 years, and 18% 
(± 11%) and 41% (±12%) at 5 years, respectively (Figure 4). 
HCCA - None of the analyzed factors were statistically associated with disease-free 
survival. However, there was a trend for lower disease-free survival in females (p=O.056 
logrank test). 
PCCA -- The only factor associated with poor disease-free survival was tumor size 
over 5 em (p=O. 024logrank test). Of the patients whose tumor size was less that 5 cm, 100% 
were rendered disease-free. 
Multivariate Analysis 
Clinical and pathological risk factors with a p-value less than 0.05, based on univariate 
analyses were incorporated into a multivariate analysis using Cox's proportional hazards 
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model. 
HCCA-- None of the clinical and pathological risk factors for mortality or disease-
recurrence met the criterion for inclusion in the multivariate analysis. 
PCCA - Multiple tumors (adjusted RR=3.50; 95% ci=1.2 to 10.5) and incomplete 
resection (adjusted RR=8.3; 95% ci=2.3 to 29.6) were independently associated with poor 
prognosis . Only tumor size greater than 5 cm was associated with disease-recurrence. 
DISCUSSION 
Although the radiological appearance of HCCA is characteristic, the preoperative 
pathologic diagnosis can be difficult (44,45). In our study, preoperative investigations, 
intraoperative findings, and pathological studies were used to delincate'HCCA from PCCA 
and to further differentiate both varieties from tumors rising in "large" bile ducts (4,6,16,20). 
There have been no previously reported series with this precise delineation of duct cell 
lesions, exclusive of those in the common and proper bile ducts. 
Assessment of the extent of HCCA with preoperative studies and intraoperative 
findings including the presence or absence of vascular invasion was crucial in deciding upon 
the optimal operation (10,36). Treatment consisted of liver resection (including the caudate 
lobe) in continuity with excision of the extrahepatic bile duct all the way to the level of the 
pancreas and lymph node dissection (10,26,28-32,34). 
During excision ofHCCA, the proximal and distal bile duct, parenchyma and vascular 
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margins were checked with frozen sections to establish clear margins, and to determine 
prognosis in cases in which there was no possibility for further dissection. The most prevalent 
postoperative complication was bile leak and abscess followed by subphrenic abscess and liver 
necrosis. Bile leak and abscess were not associated with early mortality, but subphrenic 
abscess and liver necrosis (complications often preceded by vascular reconstruction) were 
responsible for 3 deaths. 
In contrast, PCCA treatment was based primarily on liver resection, the extent of 
which was dictated by the location and dimensions of the tumor. Excision of the extrahepatic 
bile duct and lymph node dissection also were done if the malignancies were near the hilum 
or diffusely infiltrating. Vascular reconstruction was performed when necessary. As ill the 
HCCA cases, the most prevalent complication was bile leak and abscess, but only one patient 
died as a result of this complication. In both HCCA and PCCA, careful attention to technical 
details is necessary in order to avoid postoperative complications, especially those related to 
vascular reconstruction (10,46). 
Although long-term patient survival for HCCA and PCCA remains low, it can be 
achieved by aggressive surgical treatment as previously emphasized by Blumgart (28,29,36), 
Lygidakis (30-32,34), and other authors (10-12). It was clear, however, that part of the gain 
achieved by extended operations was lost because of the increased morbidity and 
postoperative mortality. The actuarial five year survival for HCCA and PCCA was 8% + 7% 
and 35 + 10%, respectively, comparable to most other studies (11,12,47), but inferior to some 
(10). Such comparisons are difficult to make because determinants other than the surgical 
treatment are so inherently influential on outcome, particularly the extent of the disease. 
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In view of the higher morbidity and postoperative mortality in the HCCA group one may 
question the justification for resection in these patients. Although resection is performed with 
a curative intent, like many other authors, most of the resections are incomplete and are only 
palliative (36,47). We as well as other authors (36,47) advocate palliative resection because 
results are better ( i.e., longer duration of survival, quality of life and long term palliation) 
than those obtained by interventional radiology techniques or surgical bypass (16, 29, 36, 
47). However this recommendation is only justifiable if the early morbidity and mortality is 
kept to a minimum. 
In order to improve early outcome we need better patient selection ( i.e., earlier 
staging of disease) and improved surgical techniques in order to avoid technical 
complications. If this can be achieved then the incomplete resection approach is certainly 
justifiable. 
For HCCA, however, none of the analyzed clinical and pathological risk factors were 
associated with patient survival. Although patients who had incomplete resection had a lower 
survival curve than those who underwent complete resection, the difference was not 
significant (p = .1437), presumably because three quarters of the patients had stage IV disease 
(22 of 28). This observation should be interpreted with caution. The inability to identify 
statistically significant prognostic factors, including a clear distinction between outcome of 
incomplete (palliative) versus complete (curative) resection, could be an artifact of the small 
sample of patients with favorable pathology. In other series, long term survival has been 
associated with complete resection (10,12). 
Five year survival was more than 4-fold higher in patients with PCCA than when the 
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diagnosis was HCCA. The only prognostic factors independently associated with poor 
prognosis were multiple tumors and incomplete resection. Eighty percent ofPCCA patients 
whose treatment was palliative (incomplete resection) had stage N disease compared to 29% 
of those considered to have had potentially curative operations (p=O.OIO; Fisher Exact test). 
Moreover, 100% of patients in the palliation group had vascular invasion. The much better 
outcome with PCCA less than 5 em has not been reported before. 
In conclusion, it is possible to occasionally obtain five year survival by resection in 
patients with HCCA and in as high as a third of those with PCCA. New adjuvant therapies 
which presumably will be based on different principles than current ones are clearly needed 
to substantially improve these results. This is particularly true for the historically fiustrating 
hilar cholangiocarcinomas whose strategic location so limits radical extirpation. 
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pTNM classification for hilar cholangiocarcinomas. 
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cholangiocarcinoma according to anatomical classification. 
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FIGURES 
Anatomic classification in patients with hilar cholangiocarcinomas. 
Overall patient survival in hilar and peripheral cholangiocarcinomas. 
Patient survival according to the type of treatment in hilar and 
peripheral cholangiocarcinomas. 
Disease-free survival in the completed resected group for hilar and 
peripheral cholangiocarcinomas. 
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Table I: pTNM Classification (Hilar Cholangiocarcinoma) 
Stage 0 TIS NO MO 
Stage I Tl NO MO 
Stage II T2 NO MO 
Stage III Tl Nl, N2 MO 
T2 Nl,N2 MO 
Stage IV-A T3 AnyN MO 
Stage IV-B AnyT AnyN Ml 
TIS: Carcinoma in situ 
Tl: Tumor invades mucosa or muscle layer 
T2 Tumor invades the peri-muscular connective tissue 
T3: Tumor invades adjacent structures: liver, pancreas, duodenum, 
gallbladder, colon, stomach 
Nl: Cystic duct, pericholedochal and/or hilar nodes 
N2: Peripancreatic, periduodenal, periportal, celiac, superior 
mesenteric, and/or posterior pancreaticoduodenal nodes 
Ml: Distant metastasis 
29 
Table IT: pTNM Classification ( Peripheral Cholangiocareinoma ) 
Stage I 
Stage IT 
Stage III 
Stage IV-A 
Stage IV-B 
TI: 
T2: 
T3: 
TI NO 
T2 NO 
TI Nl 
T2 NI 
T3 NI, NO 
T4 AnyN 
AnyT AnyN 
Solitary ~ 2 em, without vascular invasion 
Solitary ~ 2em, with vascular invasion 
Multiple, one lobe, ~ 2 em, without vascular invasion 
Solitary, > 2 cm, with vascular invasion 
Solitary, > 2 em, with vascular invasion 
MO 
MO 
MO 
MO 
MO 
MO 
MI 
Multiple, one lobe, > 2 cm, with or without vascular invasion 
T4: Multiple, > one lobe 
Invasion of major branch of portal or hepatic veins 
Nl: Regional node metastasis 
MI: Distant metastasis 
30 
Table ill: The type of liver resection performed in 28 patients with hilar cholangiocarcinoma according to anatomical 
classification. 
I 
Anatomical Classification: 
ma(n=7) 
IIIa+ (n=3) 
IIIb (n=7) 
IV (n=l) 
IVa (n=2) 
IVb(n=2) 
V(n=2) 
Unknown(n=4) 
Nwnber of patients: 
Nwnber of deaths within 30 days of 
the operation: 
KEYS: 
RT -L: Right lobectomy 
EXT -R: Extended right lobectomy 
RT-T: Right trisegmentectomy 
I RT-L I EXT-R I RT-T 
I ------ 6 
1 ------ 2 
------ ------ ------
------ ------ -... ---
------
1 I 
------ ------ --------
------ ------ -------
------ ------
----_ .. 
2 1 9 
I 1 
LT-L: Left lobectomy 
EXT -L: Extended left lobectomy 
31 
I LT-L I EXT-L I LT-T 
------ ------
-----
------ ------ -----
4 3 -----
------
1 -----
------ ----- -----
1 1 -----
1 1 -----
1 1 1 
7 7 I 
2 
LT-T: Left trisegmentectomy 
CE: Central excision 
I CE I 
------
------
------
------
------
--_ .. --
------
1 
1 
Table IV: The distribution of potential prognostic factors according to type of tumor. 
I Factor I HCCA I PCCA I 
SexMIF 15113 11123 
Age (years)' mean ± ds 56± 12 59±8 
Tumor Size ~ 5 em 3 (19%) 26 (76%) 
Tumor Distributionb 
Unilobar N/A 21 (62%) 
Bilobar 13 (38%) 
Number of TumorsC N/A 
Single 18 (53%) 
Multiple 16 (47%) 
Tumor Differentiationd 
Well 8125 (32%) 4121 (19%) 
Moderate to poor 17125 (68%) 17/21 (81%) 
Vascular Invasion 
Yes 15 (54%) 24 (71%) 
Lymph Node Involvement 
Yes 13 (46%) 6 (18%) 
Type of Treatment 
Complete resected 14 (50%) 24 (71%) 
Incomplete resected 14 (50%) 10 (29'>/0) 
Underlying Cirrhosis 
Yes 5 (18%) 2(6%) 
Tumor Stage 
I, II. or III 6(11%) 19 (56%) 
IV-a or IV-b 22 (79%) 15 (44%) 
Adjuvant Therapy" 
Yes 22/24 (92%) 24/32 (75%) 
Anatomic Classificationf 
III-a 7 (25%) 
III-a + 3 (11%) 
III-b 7 (25%) 
IV 1 (4%) nla IVa 2(7%) 
IVb 2(7%) 
V 2(7%) 
Unknown 4(14%) 
a = age (in years) at time of hepatic resection 
b = for HCCA patients, the tumor usually involves bifurcation of the common hepatic bile duct 
c = for HCCA patients, there is no discrete liver mass 
d = three patients with HCCA and eleven patients with PCCA tumor differentiation unknown 
e = post-operative radio-and/or chemotherapy for these patients who survived at least 30 days following surgery 
f = anatomic classification only for HCCA patients 
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Anatomical Classifications in Patients with 
Hilar Cholangiocarcinomas 
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